Official Title: PHASE 1, OPEN-LABEL DOSE-FINDING STUDY TO EVALUATE SAFETY, TOLERABILITY, AND IMMUNOGENICITY AND PHASE 2/3 PLACEBO-CONTROLLED, OBSERVER-BLINDED SAFETY, TOLERABILITY, AND IMMUNOGENICITY STUDY OF A SARS-COV-2 RNA VACCINE CANDIDATE AGAINST COVID-19 IN HEALTHY CHILDREN and Young Adults
https://www.clinicaltrials.gov/ct2/show/NCT04816643
Estimated Study Completion Date : June 18, 2024
Experimental: High-Dose, ≥6 Months to <2 Years
High-Dose, (30mcg), 2 doses 21 days apart
That’s phase 1 that is in a very limited number of subjects. The large dose was the full adult dose of 30 mcg. Phase 3 is the large study. They dose picked for the Phase 3 trial for children 5-11 was 10 mcg which is one-third the adult dose. I see that they also had an experimental trial for a lower dose for the 16 - 30 age group.